Solo advances

Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. *Blood Adv.* 2019;3(21):3241-3247.

A copy of the article's visual abstract was erroneously published as the supplemental data file. It has been replaced by the correct supplemental data file.

© 2020 by The American Society of Hematology

DOI 10.1182/bloodadvances.2020002987